AUTHORS
Vidhi Bhanushali, MBBS, Charmi Bhanushali, MD2, Nikhil Verma, MD3, Vidit Majmundar, MD4, Pragya Jain5, Alan Baltz, MD6, Mamatha Gaddam, MD7, Carolina D Schinke, MD8, Cesar Gentille Sanchez, MD9, Ankur Varma, MD10, Muthu Kumaran, MD11
AFFILIATIONS
1 University of Arkansas for Medical Science, Little rock, Arkansas, United States
2 HCA Florida Westside, Miami, United States
3 University of Arkansas for Medical Science, Little rock, Arkansas, United States
4 University of Miami, Miami, Florida, United States
5 Baptist Hospital of Southwest, Beaumont, Texas, United States
6 University of Arkansas for Medical Science, Little rock, Arkansas, United States
7 University of Arkansas for Medical Science, Little rock, Arkansas, United States
8 University of Arkansas for Medical Science, Little rock, Arkansas, United States
9 University of Arkansas for Medical Science, Little rock, Arkansas, United States
10 University of Arkansas for Medical Science, Little rock, Arkansas, United States
11 University of Arkansas for Medical Science, Little rock, Arkansas, United States
ABSTRACT
Background:
Treatment landscape in myelodysplastic syndrome has evolved drastically over the past decade. The aim of the study is to characterize the trends in Medicare spending and utilization for major MDS therapies from 2013-2022.
Methods:
A retrospective cross-sectional analysis was conducted using publicly available Medicare Part B and Part D claims data. Data for azacitidine, decitabine, luspatercept, venetoclax (Venclexta and Venclexta starting pack), and the oral hypomethylating agent (HMA) combination decitabine/cedazuridine (Inqovi) was extracted from 2013 – 2022. Variables included annual total spending, total dosage units, claims, and average spending per dosage unit and per claim. All the financial values were adjusted for inflation by adjusting to 2,022 dollars using the Consumer Price Index (CPI-U). Compound annual growth rates (CAGRs) in average spending per dosage unit were calculated for an early period (2013–2017) and a late period (2018–2022), or from the first year of available data for newer agents.
Results:
Total spending and average spending per dosage unit on Injectable HMA declined sharply. The total spending for azacitidine decreased nearly 10 times from $276.5 million in 2013 to $26.5 million in 2022. This was primarily due to a decrease in average spending per dosage unit from $6.85 to $0.68, as dosage units and beneficiaries remained relatively stable. Decitabine showed similar trajectory, where total spending fell from $172.7 million to $8.0 million with average spending per dosage unit from $41.41 to $2.13. While CAGRs in average spending per dosage unit were consistently negative for both agents, decitabine showed a much more accelerated decline from - 15.5% in 2013–2017 to - 32.2% in 2018–2022.
Luspatercept, approved 2019, showed increased spending after introduction from $120.5 million in 2020 to $333.0 million in 2022. This growth was driven by increased total dosage units (from 2.80 million to 8.98 million), while average spending per dosage unit remained relatively similar. This is reflected in 3.46% increase between 2021 and 2022 and a slightly negative CAGRs in average spending per dosage unit (-1.3%) over 2020–2022.
Utilization of part D drugs rose substantially. Spending on Inqovi, approved in 2020, increased from $9.0 million to $69.6 million by 2022, with dosage units increasing from 5,945 to 43,034 and claims from 1,183 to 8,816. Average spending per dosage unit showed only a modest decline, corresponding to a compound annual growth rate of -1.35% over 2020–2022 and a change of - 4.1% from 2021 to 2022.
Venetoclax total spending increased 15 fold, from $51.0M to $757.6M with dosage units increasing from 513,697 to 6.64 million and a CAGR in average spending per dosage unit of +5.0%. Venetoclax starting pack spending increased approximately 5 fold, with a CAGR of +2.3%.
Conclusion
Over the past decade, Medicare spending on MDS-related therapies has undergone a significant redistribution rather than an overall reduction. Per-unit reimbursement for HMAs under Part B declined substantially, likely due to generic competition and pricing pressure. In contrast, spending on luspatercept (Part B) and oral HMAs (Part D) rose markedly, driven primarily by rapid growth in utilization. Venetoclax and Inqovi spending increased across Part D, but these trends cannot be attributed solely to MDS because of its use in one other hematologic malignancy. These findings indicate that therapeutic innovation in MDS is reallocating costs from Part B drugs to newer Part B and Part D therapies. These spending patterns have potential implications for patient out-of-pocket costs and access. High cost oral cancer drugs often carry specialty tier coinsurance and complex benefit phases rather than the more predictable cost-sharing typical of Part B infusion drugs. The analysis does not capture manufacturer rebates or discounts and does not account for changes in MDS prevalence over time. Future studies using patient-level, disease-specific data are needed to more precisely quantify the economic and affordability impact of the evolving MDS treatment landscape.
DISCLOSURES
Vidhi Bhanushali, MBBS: No relevant conflicts of interest to declare.